According to the numerous reports which have appeared in the literature during the past year, sulfanilamide (paraaminobenzenesulfonamide) therapy has continued to hold a prominent place in the successful treatment of pneumococcic, 1 meningococcic 2 and gonococcic 3 infections and others, of a much more remote cause, as well as those caused by hemolytic streptococci. 4 The fact that the immediate toxic effects have been relatively few has been an added impetus to the more extensive administration of sulfanilamide. Some toxic reactions have been easily compensated for by the withdrawal of the drug, while others, of a more serious nature, such as acute hemolytic anemia 5 and agranulocytosis, 6 are probably attributable to idiosyncrasies, according to Marshall and his co-workers. 7 Many theories have been advanced to explain the mode of action of the drug. Domagk, 8 as the result of experiments in the treatment of experimental streptococcic infections in mice, reported that the phagocytosis of the streptococci by
No takes yet. Share an insight, caveat, or question.
B. J. MCMAHON (1938) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: